Wall Street Zen Upgrades Turn Therapeutics (NASDAQ:TTRX) to Hold

Turn Therapeutics (NASDAQ:TTRX) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Other analysts also recently issued reports about the stock. Weiss Ratings raised shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a report on Monday. D. Boral Capital reiterated a “buy” rating and issued a $8.00 target price on shares of Turn Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.00.

Turn Therapeutics Stock Up 1.0%

TTRX opened at $9.12 on Friday. The business has a 50 day moving average price of $6.34 and a 200 day moving average price of $4.67. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23. The firm has a market cap of $271.68 million and a P/E ratio of -48.00.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter.

Institutional Investors Weigh In On Turn Therapeutics

Several hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Turn Therapeutics in the fourth quarter worth $377,000. DDFG Inc boosted its holdings in Turn Therapeutics by 34.9% in the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares during the period. Wellington Shields & Co. LLC acquired a new stake in Turn Therapeutics in the 4th quarter worth $259,000. XTX Topco Ltd acquired a new stake in Turn Therapeutics in the 4th quarter worth $99,000. Finally, Brown Brothers Harriman & Co. bought a new position in shares of Turn Therapeutics during the 4th quarter worth about $93,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.